EGFR and non-small cell lung carcinoma: Cur analog CUCM-36 targets EGFR to prevent NSCLC via diverse mechanisms, whereas the actual synthesis of the CUCM-36 compound is required to verify its anti-EFGR action in vivo and in vitro [158].